The effects of Hyaluronic acid and Atorvastatin on knee arthrosis

A clinical trial to Compare between the efficacy of of intra-articular Hyaluronic acid and oral atorvastatin in reducing pain, stiffness, and function of the knee in patients with mild to moderate knee osteoarthritis

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201504141479N4

Enrollment

Registered

2015-08-17

Start date

2014-04-04

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

knee osteoarthritis. Gonarthrosis [arthrosis of knee]

Interventions

Intervention 1: Group 1: After sterilizing the injection site, we inject one ampoule of Hyaluronic acid (Hyaluron® HEXAL, Germany,20mg/2cc) into the knee joint. We repeat the injection each week for t

Treatment - Drugs

Group 1: After sterilizing the injection site, we inject one ampoule of Hyaluronic acid (Hyaluron® HEXAL, Germany,20mg/2cc) into the knee joint. We repeat the injection each week for three times

Group 2: Oral atorvastatin 40 mg (Sobhan Darou, Tehran, Iran) one tablet daily for 6 months

Eligibility

Sex/Gender

All

Age

50 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria 1- Knee osteoarthritis according to ACR criteria 2- Age 50-70 years 3- Radiologically ascertained grade I or II of knee osteoarthritis on the Kellgren-Lawrence scale 4- Pain score=>60 (maximum 100) Exclusion criteria 1- Secondary osteoarthritis 2- Systemic disease like diabetes 3- History of Inflammatory arthritis 4- Sever knee deformity (varus or valgus >50 degree) 5-History of coagulopathies 6- Sever cardiovascular disease 7- Active infections 8- Immunologic disorders 9- Taking anticoagulants 10- Hb<11 mg/dl, platelet count<150000/dl

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Knee osteoarthritis symptoms: knee pain, knee sitffness and knee function. Timepoint: At enrollment and after intervention : every month up to 6 months. Method of measurement: WOMAC questionnaire.	—

Secondary

Measure	Time frame
Drug side effects: in group 1: hypersensitivity reaction in injection site and exacerbation of knee pain. In group 2: musculoskeletal pain, skin rash and gastrointestinal symptoms. Timepoint: Every 1 month after intervention up to 6 months. Method of measurement: Taking history.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Hassan Jokar

Mashhad University of Medical Sciences

jokarmh@mums.ac.ir jokarmh@gmail.com mirfeiziz@mums.ac.ir+98 51 3859 8818

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026